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SObjective: Our objective was to evaluate whether resection and heated pleural chemoperfusion (HPCP) is an
effective treatment for de novo stage IVa thymoma (DNT) and thymic carcinoma (TC) and for thymoma
with pleural relapse (TPR).
Methods: A retrospective study was conducted of patients undergoing resection and HPCP in 1 center. HPCP
with cisplatinum  doxorubicin (adriamycin) was performed for 60 minutes using a standard roller pump and
a modified heat exchanger to a maximal intrapleural temperature of 43C. Follow-up included at least 1 annual
computed tomographic scan until death or March 2012.
Results: Thirty-five patients, 17 DNT, 14 TPR, and 4 TC, completed 42 intended treatments and were followed
up for 4 to 202 months (median, 62 months). Seven patients had repeated HPCP at an interval of 2 to 12 years.
There was no systemic toxicity. Ninety-day mortality was 2.5%. Major and minor morbidity occurred in 12%
each. Five-, 10-, and 15-year overall survivals for DNT, TPR, and TCwere 81%, 73%, 58% (DNT), 67%, 56%,
28% (TPR), and 0%, 0%, 0% (TC). Five- and 10-year progression-free survival was 61%, 43% for DNT and
48%, 18% for TPR. Presently, 11 of 17 DNT patients are alive (6, no evidence of disease), and 8 of 14 TPR are
alive (6, no evidence of disease). Median survival for thymoma was 157 months. Overall survival was unrelated
to any preoperative or intraoperative variable. Progression-free survival was improved in R0 compared with
R1-2 resection (P<.001). Local control achieved in 21 (57%) of 37 procedures in thymoma patients was related
only to completeness of resection (P ¼ .015).
Conclusions: (1) Lung-sparing resection and HPCP is feasible and safe. (2) In thymoma with pleural spread it
offers excellent survival despite moderate pleural control. (3) Preliminary results with stage IVa TC are disap-
pointing. (J Thorac Cardiovasc Surg 2013;145:83-9)Thymic epithelial tumors (TET) are relatively uncommon
neoplasms, the majority of which are discovered in early
operable stages. About 7% of thymomas present at de
novo stage IVa thymoma (DNT) and are associated with
5- and 10-year survivals of 59% and 36%, respectively.1
Thymic carcinoma (TC) is a rare tumor, presenting usually
at advanced stages and associated with a poor prognosis.
Although the relapse rates for stage I-III thymoma are rela-
tively low,1 more than 50% of these occur in the pleural
space (thymoma with pleural relapse, TPR) and thereafter
have an unfavorable fate.2,3
The literature pertaining to TET with pleural spread,
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The Journal of Thoracic and Cbeen treated with chemotherapy alone4 but, more often, in
a multimodality manner that almost always includes sur-
gery.5,6 The surgical arm varies from debulking7,8 to radical
and, occasionally, as extensive as pleuropneumonectomy9,10
or extrapleural pneumonectomy.11,12 Owing to the small
cohorts of TET with pleural spread and the versatility of
treatment options, the preferred approach for this condition
has not been established.
Dissatisfied with the reported results and our own experi-
ence and learning from experience with pleural chemother-
apy in mesothelioma and malignant effusions,13-15 we
embarked as early as 1995 on a new management
protocol consisting of surgical resection plus heated
pleural chemoperfusion (HPCP). Preliminary reports with
a small group of patients were reported in 2001.16,17 The
current study aims to analyze the operative results and the
long-term outcome of a relatively large cohort in an attempt
to verify whether it could be recommended as an acceptable
treatment for TET with pleural spread.PATIENTS AND METHODS
Included in this study are all patients with TET and pleural spread who
underwent surgery plus HPCP since 1995. They were either referredardiovascular Surgery c Volume 145, Number 1 83
Abbreviations and Acronyms
DNT ¼ de novo stage IVa thymoma
HPCP ¼ heated pleural chemoperfusion
TC ¼ thymic carcinoma
TET ¼ thymic epithelial tumor
TPR ¼ thymoma with pleural relapse
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Sselectively by other institutions or taken from our own pool, in which case
all patients with pleural spread were discussed in a multidisciplinary meet-
ing. Patients (n ¼ 2) with major chest wall involvement were considered
unsuitable for this treatment. Data were acquired from a prospective data-
base and, when necessary, admission charts were pulled and reviewed.
Follow-up information was gathered from outpatient records, telephone
conversations, and the national demographic registry. The study was ap-
proved by the institutional ethics committee and the off-label use of the
chemotherapeutic agents by the institutional pharmacologic board.
Follow-up was scheduled at 6-month intervals and computed tomo-
graphic scans were performed at a minimum of 1 annually. Other studies
like positron emission tomography–computed tomography, magnetic reso-
nance imaging, octreotide scans, and biopsy were ordered on an individual
basis.
Histologic material was revised by an experienced thoracic pathologist
(M.P.) using hematoxylin and eosin stain and classified according to the
2004 World Health Organization. ‘‘Mixed thymomas’’ were designating
by the predominant cell type, which comprised more than 50% of the sub-
mitted sections.
The number of pleural implants (from 2 to infinite) and the total implant
volume (1-350 mL3) were recorded for every procedure.
Preoperative and Postoperative Treatments
All of the TC patients and 13 of the 31 thymoma patients received che-
motherapy at some point before HPCP, with a response rate of 88%. We
have not used chemotherapy intentionally in a neoadjuvant setting. Full de-
tails as to the exact agents and doses are lacking, inasmuch as those were
administered in many institutions. Radiation therapy was used in 8 TPR pa-
tients after their initial operation.
Adjuvant chemotherapy was administered to patients with TC or to thy-
moma patients with pleural R2 resection. Adjuvant radiotherapy was used
in DNT patients with R1-R2 resection of their mediastinal component. In
other patients, these modalities were reserved for the management of local
or systemic relapses on an individual need to treat basis.
Surgical Approach
Surgery was aimed toward complete resection of any mediastinal in-
volvement and gross resection of all pleural disease. Partial pleurectomy
was performed mainly on the chest wall pleura. Diaphragmatic implants
were removed along with partial muscle thickness when required. Visceral
pleural implants were removed locally or by wedge excision. Pneumonec-
tomywas avoided as far as possible. In this report R1 and R2 resection were
grouped together as incomplete resection.
Chemoperfusion
Perfusion was performed in a routine manner described by us previ-
ously.13 In essence, it was done in the supine position after final closure
of the incision, using 2 28F chest tubes connected to a standard roller
pump and a heat exchanger, which was modified in 1999 to allow an output
of 45C. The amount of perfusate varied from 1500 to 3500 mL. The
perfusion was initiated without the chemotherapeutic agents. When the
temperature stabilized, 100 mg/m2 of cisplatinum and since 2002 also84 The Journal of Thoracic and Cardiovascular Surgea 50 to 60 mg total dose of doxorubicin were added. Perfusion was carried
out for 60 minutes at a flow of 1000 to 2500 mL/min. Pleural temperature
was considered as the mean of the input and output temperatures as
determined by earlier studies with an intrapleural temperature probe.
Flow rates were adjusted as required to maintain the set temperature
and hemodynamic stability. Renal protection was accomplished with ade-
quate preperfusion hydration and maintaining a urine output of more than
80 mL/h.
On 2 occasions, HPCP was delayed for a few days owing a very lengthy
operation associated with hemodynamic instability.
Statistical Analysis
Survival analysis was performed by the Kaplan-Meier method and was
calculated from the date of the first HPCP using SPSS software (SPSS, Inc,
Chicago, Ill). We used the term disease-free progression rather than
disease-free survival because it is doubtful whether R0 resection can indeed
be achieved in stage IVa TET unless extrapleural pneumonectomy is per-
formed. For morbidity and mortality figures the denominator used was
the number of operations. To examine combined effects of various factors
on overall and progression-free survival and on local control, we used non-
parametric tests, that is, c2 and Mann-Whitney.
RESULTS
Forty patients were considered for surgery and HPCP.
Five were rejected: 2 owing to TC histology (after midterm
analysis of the early experience), 2 because of major
chest wall involvement, and 1 intraoperatively owing to
complete macroscopic and microscopic pleural response.
The remaining 35 patients were divided into 3 groups: TC
(n¼ 4), DNT (n¼ 17), and TPR (n¼ 14). The demographic
and clinical parameters are summarized in Table 1. The ma-
jority of thymoma patients had B2 histology and 15
(48.4%) had myasthenia gravis at diagnosis.
Reoperation was performed in 11 patients with disease
progression, of whom 4 did not continue to HPCP owing
to liver metastases (n¼ 1), minute space (n¼ 1), single im-
plant (n ¼ 1), and hemodynamic instability (n ¼ 1). The
data pertaining to these 7 patients (redo HPCP) were added
to Table 2, which summarizes the surgical and perfusion re-
sults. As a group, they were obviously older (mean age, 55
years) than the 35 ‘‘original cohort.’’
Mortality and Morbidity
The 90-day mortality was 2.5% (1 patient) owing to em-
pyema complicating a redo operation 14 years after the ini-
tial HPCP. Another patient died 11.5 months after
pneumonectomy, superior vena cava resection and recon-
struction, and partial resection of both atria from a broncho-
pleural fistula. Nonfatal complications occurred after 11
procedures: DNT, 3; TPR, 4; TC, 2; and redo, 2 (27%),
including grade III/IV nausea (n ¼ 3), prolonged air leak
(n ¼ 2), bleeding requiring reexploration (n ¼ 1), and
pneumonia (n ¼ 1), all occurring in the early postoperative
period. Delayed morbidity consisted of myasthenic crisis
(n ¼ 2), chronic respiratory failure (n ¼ 1), and purulent
pericarditis with sepsis (n ¼ 1). The later was the sole
patient who had supraventricular tachycardia.ry c January 2013
TABLE 1. Patient characteristics (n ¼ 35)
DNT TPR TC
Patients (no.) 17 14 4
Age (y)
Median 52 44 50
Range 22-67 25-62 20-70
Gender, male/female 14:3 8:6 3:1
Histology
AB 2
B1 2 3
B2 12 5
B3 3 4
TC 4
Myasthenia gravis 6 9 0
Diagnosis–HPCP interval (median) 6 wk 4 y 8 mo
Previous chemotherapy (response) 9 (8) 5 (4) 4 (3)
Previous radiation 2 8 0
Previous surgery
Resectional 2 14 1
Diagnostic 4
Side
Right 7 4 3
Left 9 10 1
Bilateral 1
DNT, De novo stage IVa thymoma; TPR, thymoma with pleural relapse; TC, thymic
carcinoma; HPCP, heated pleural chemoperfusion.
FIGURE 1. Overall survival for thymoma (de nono stage IVa thymoma
[DNT] and thymoma with pleural relapse [TPR]) and thymic carcinoma
(TC) (n ¼ 35).
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toxicity.Long-Term Outcomes
Thymic carcinoma. Local control was achieved in none of
the patients in this group and all died within 4 years (mean,
33 months) of distant disease spread despite aggressive sys-
temic therapy (Figure 1).TABLE 2. Surgical and perfusion data (n ¼ 41)
DNT
(n ¼ 17)
TPR
(n ¼ 14)
Redo
(n ¼ 7)
TC
(n ¼ 4)
Maximum procedure
Local resection 4 5 3 1
Pleurectomy 2 6 1
Wedge/lobectomy 3/1 1 2
Chest wall 3 2 2 2
Diaphragm 1
Vena cava 2
Pleuropneumonectomy 1
Atrium
Resection R0:R1:R2 7:9:1 6:6:2 4:1:2 1:1:2
Chemotherapeutic agents
Cisplatinum 100 mg/m2 16 14 7 4
Doxorubicin 8 10 5 0
Perfusion temperature
41.8C 6 6 2
>41.8C 11 8 7 2
DNT, De novo stage IVa thymoma; TPR, thymoma with pleural relapse; TC, thymic
carcinoma.
The Journal of Thoracic and CThymoma. Deaths occurred from 7months to as long as 14
years after surgery equally in both groups, only 4 of them
owing to systemic disease progression (7, 30, 51, and 106
months after surgery). One died of a second primary neo-
plasm, 1 is still alive with widespread metastases, and 2
have probably been cured of early-stage malignant disease
(lung and prostate). Thus the rate of second neoplasms in
our series was 13%. Two deaths in myasthenic patients
were attributed to pneumonia, and 2 may have been due to
thymus-related syndromes. One patient died at the age of
82 years of right heart failure. Interestingly, none of the
14 myasthenic patients had complete neurologic remission.
The median follow-up for all patients was 62 months
(range, 3.5-202 months). The 5, 10, and 15-year overall sur-
vivals for DNT and TPR were 80.8%, 72.7%, and 58.2%
(DNT) and 66.7%, 55.6%, and 27.8% (TPR) (Figure 1).
The median survival was 184 months (95% confidence in-
terval, 120.5-247.5) for DNT and 140 months (95% confi-
dence interval, 34.3-245.7) for TPR. The 5- and 10-year
progression-free survivals were 60.6% and 43.3% for
DNT and 47.6% and 17.9% for TPR (Figure 2). The
10-year disease-specific survivals for DNT and TPR were
79% and 87.5%, respectively (Figure 3).
Using the Mann-Whitney test, only the extent of resec-
tion (complete responders vs incomplete responders) pre-
dicted disease-free survival (Z ¼ 3.71; P<.001). Local
control was related to the same variable using the c2 test
(complete responders, 25% relapse, vs incomplete re-
sponders, 65%; P ¼ .015).
DISCUSSION
This retrospective study establishes the feasibility and
safety of HPCP after resection in TET patients withardiovascular Surgery c Volume 145, Number 1 85
FIGURE 2. Progression-free survival for de novo stage IVa thymoma
(DNT, n ¼ 17) and thymoma with pleural relapse (TPR, n ¼ 14).
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with no systemic toxicity, 2.5% 90-day mortality, and
a major morbidity of 12.5%. The 10-year overall survival
of 73% is among the best ever reported. Similar results
were achieved by Huang and associates11 in a series of
18 patients undergoing extensive resections. These rates
are superior to the 40% figure commonly found in the
literature.18-20 Unfortunately, the recommendation to
perform extrapleural pneumonectomy was recently met
with frustrating results: 90-day mortality of 29%,FIGURE 3. Cause-specific survival for de novo stage IVa thymoma
(DNT) and thymoma with pleural relapse (TPR).
86 The Journal of Thoracic and Cardiovascular Surgemajor morbidity of 47%, and 10-year overall survival
of 30%.10
Reports pertaining to stage IVa thymoma are difficult to
compare. Patients included in such small studies usually
differ in many parameters. For example, in our series the in-
cidence of myasthenia was 48%, whereas it was 29% in the
report by Fabre and associates10 and 0% in that of Huang
and colleagues.11 One must recall that myasthenia and its
treatment may contribute to excessive operative morbidity
and mortality,10 as well as to late deaths.Without the knowl-
edge of the causes for late mortality, results are difficult to
interpret. Thus in our series only 4 patients died of disease
progression, whereas all other late deaths were not cause
specific, including 2 probably attributed to thymus-related
syndromes and 1 to a second primary neoplasm.
Another confounding factor is the follow-up periods.
Some studies have reported only mean follow-up period,
which is usually meaningless. In others, the median
follow-up varies from less than 1 year to as much as 98
months,8 although the last figure is probably miscalculated.
With a minute number of patients at risk at the 5- and
10-year points, the actuarial survival figures may differ con-
siderably from the actual rates.
Other factors that may affect survival, and certainly local
relapse, are the number of pleural implants and tumor bur-
den. Two studies addressed the first issue. Overall survival
was found to be significantly better in patients who had sin-
gle versus multiple relapse lesions2 or 1 to 2 versus 3 or
more pleural implants.3 In our series, only 6 patients had
fewer than 3 lesions and the majority had numerous im-
plants. As expected, this variable had no statistically signif-
icant effect on overall survival and progression-free
survival as well as on local control. Tumor burden has not
been studied previously as a possible prognosticator. In
our study, this variable had no effect on the outcome. Local
control may be affected also by additional variables related
to tumor biology (classification, interval from thymectomy,
chest wall invasion, and response to previous treatments),
the significance of which is difficult to assess in small stud-
ies. Operative variables possibly play a role. Completeness
of resection is certainly important in stages II and III and
perhaps also in stage IVa, as some studies discussed here
have demonstrated. In our study, it had a significant effect
on local control and progression-free survival. Although
we, like others, doubt whether R0 resection is indeed
achievable when widespread pleural seeding is present, it
seems that the combined surgical–pathologic resection sta-
tus correlates with some end points. We also attempted to
evaluate variables pertaining to our specific management.
Of those, only the perfusion temperature may play a role.
The specific chemotherapeutic agents used and their con-
centration failed to show any impact on the end points stud-
ied. In a pleural and abdominal perfusion study in patients
with mesothelioma, Tilleman and associates21 have usedry c January 2013
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Scisplatinum doses as high as 225 mg/m2. Doses higher than
100 mg/m2 could be tested also in thymoma patients.
The results of our study highlight a few interesting points:
(1) Patients may survive for prolonged periods despite dis-
ease relapse. (2) Freedom from relapse does not ensure lon-
gevity owing to late deaths from nonthymomatous causes.
(3) Myasthenia in patients with stage IVa disease tends to
persist. (4) There is a moderate rate of contralateral pleural
relapse. (5) More than 10% of the patients are expected to
have a second primary neoplasm. Pleuropneumonectomy,
or extrapleural pneumonectomy in myasthenic patients
and after neoadjuvant chemotherapy, may be associated
with considerable mortality. Considering the entire spec-
trum of these facts along with life quality, we believe that
the approach proposed by us, that is, lung-preserving resec-
tion plus HPCP, may emerge as the preferred treatment for
thymoma patients with pleural spread.
Our study has some of the usual weaknesses of a single-
center nonrandomized study: selection bias and confound-
ing variables. The fact that the response rate to preoperative
chemotherapy in thymoma patients was 88% points to a se-
lection bias from referral centers. The contribution of vari-
ous preoperative and postoperative modalities to survival
could not be analyzed owing to a great variation in means
and timing. A large prospective multicenter trial may over-
come these shortcomings.References
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Dr Joshua R. Sonett (New York, NY). Dr Yellin, thank you for
the delivery of your manuscript and your slides over a month be-
fore the presentation.
I have nothing to disclose except to personally thank you for
helping bring this modality to Columbia over 7 years ago. I am
glad to say that the patient you introduced this therapy to at Colum-
bia is doing quite well.
Your group has to be complimented as one that thought outside
the box about locoregional treatment before it was fashionable and
is assessing it quite soberly and objectively even as you advocate it
as a possible standard.
I have some general points of discussion and 3 questions. Your
best results, as one might expect, were in R0 resections, as with
virtually all thymic resection series. Many would thus argue that
these patients do not need this therapy. Can you tackle this ques-
tion and also help sort out how to definitively prove this is a signif-
icant therapeutic advance, especially given the overall slow
progression of many of these patients and the ability to give sub-
sequent systemic chemotherapy?
Induction chemotherapy for locally advanced thymoma appears
to be effective in reducing tumor burden and increasing R0 resec-
tions. Would you at present advocate or consider systemic chemo-
therapy before your operative treatment with known stage IV
disease to increase your R0 resection preoperatively?
Finally, at Columbia we have pretty much copied your model
for advanced thymoma. However, in pleural mesothelioma we
have developed a model of repeated intrapleural dosing. If chemo-
therapy given once intraoperatively is of probable but not proven
value, why stop at a single dose? All conventional cancer chemo-
therapy is given repeatedly. Repetitive chemotherapy kills a greaterardiovascular Surgery c Volume 145, Number 1 87
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refractory state. We have thus far shown in patients with pleural
mesothelioma that such chemotherapy can be given over
a 2-month period via indwelling intrapleural catheters, repeated
quite safely and easily. So should we consider this model for stage
IV thymomas, followed by a final resection and heated
chemotherapy?
I thank you and again congratulate you on your pioneering
work.
Dr Yellin. Thank you, Dr Sonett, for your kind remarks and
thoughtful input.
I personally doubt that R0 resection is indeed achievable, al-
though formally that is the case. The philosophy behind the perfu-
sion is to treat invisible small implants. R0 resection yielded the
best results as far as local control was concerned, but it had no im-
pact on overall survival. Unfortunately, the proof that perfusion
has an advantage over any other modality requires a phase 3 study,
which probably will never take place.
Preoperative chemotherapy in our patients was given sporadi-
cally in an unplanned manner. It was not in a neoadjuvant setting.
From our data, it seemed effective but had no impact on the results.
Nevertheless, faced with an invasive mediastinal thymoma or
bulky implants, I would recommend neoadjuvant therapy.
The third question is certainly very interesting. Before address-
ing it, I have to mention a few facts. First, pharmacokinetic studies
have shown that in the perfusion setting, cisplatinum serum con-
centration is almost 0 after 24 hours, which allows for a second
dose. Second, cisplatinum absorption is higher in patients under-
going limited resection compared with those who undergo extrap-
leural pneumonectomy. Third, perfusion is followed very quickly
by severe adhesions. Therefore, I believe that we could indeed re-
peat the dose, but only in a time frame of about a week, not very
much longer. We certainly should consider it. Thank you for the
idea.
Dr David J. Sugarbaker (Boston, Mass). You chose platinum
and doxorubicin as your 2 drugs. In terms of dosing, inasmuch as
there are no data on the appropriate dose of chemotherapeutic
agents placed intrathoracically, do you think that you might be
better served by performing a phase 1 trial to establish the max-
imum tolerated dose? We have done that with mesothelioma, as
presented earlier today. We achieved a dose that was several
times higher than the dose that is given intravenously, 225 versus
100 mg/m2. If you remember Hill’s postulates on the effective-
ness of chemotherapy, effective chemotherapy improves survival
as one is able to increase the concentration and/or dose of
the drug.
I have 2 questions. First, you selected doxorubicin and plati-
num. In the United States, that is not a commonly administered
chemotherapeutic regimen for stage IV thymoma. Second, do
you think that additional studies of the phase 1 type which would
allow for dose escalation and triplets would allow you to maximize
the effect of chemotherapy?
DrYellin.We chose cisplatinum and doxorubicin because those
are 2 of the most common drugs given for thymoma at large and
those are the drugs that worldwide have the largest experience.
We know most about the pharmacokinetics, the side effects, and
so on. We were concerned with the higher doses you have reached
because, with an intact pleura, we should expect higher serum88 The Journal of Thoracic and Cardiovascular Surgelevels, and therefore toxicity could be a bit higher than is seen in
other studies.
Dr Sugarbaker. Are you trying to get all macroscopic disease
resected, in which case I would assume that the pleura was also re-
sected? Is that not the case?
Dr Yellin. Not necessarily. In most cases we did not perform
a total pleurectomy, only a partial pleurectomy. Certainly, the vis-
ceral pleura was intact and part of the mediastinal pleura was intact
and the diaphragmatic pleura stayed intact. We had enough of an
absorption area to increase serum levels.
Dr Sugarbaker. Do you think that all that retained pleura,
which is invariably seeded with tumor cells, may be responsible
somewhat for the survival that you noted? Do you think you might
be better off to do a complete, radical pleurectomy in these cases if
you are not going to do an extrapleural pneumonectomy?
Dr Yellin. Perhaps, but the survival results are at least compa-
rable with those with extrapleural pneumonectomy, and therefore
I am not sure it is indeed required.
Dr Mark J. Krasna (Neptune, NJ). I enjoyed the presentation
and again congratulate you and your group for pushing this for-
ward for many, many years.
As we heard this morning in the mesothelioma talk by Dr Sugar-
baker, it sounds like your group is now using it, and now you are
talking about putting it into a phase 2 study. The message that I
would like to understand is, first, are you ready to say to us that
in prime time we should do this? Are you advocating that off pro-
tocol we should be using intrapleural chemotherapy for the stage
IV diseases, whether you do it as an extrapleural pneumonectomy
or an en bloc macroscopic resection? My second question to both
you and Dr Sugarbaker is, if not, can we get a cooperative group
study? I know many years ago we tried to do a cooperative group
study for mesothelioma to test your phase 2 hypothesis, David. Is it
time to do either a national or international phase 2 or phase 3, ei-
ther in the thymic group or the mesothelioma?
Dr Yellin. I certainly advocate it, but, unfortunately, the Inter-
national Thymic Malignancy Interest Group has decided that an-
other venue is maybe preferred owing to technical difficulties
and institutional review board problems and so on. I believe this
is the best thing to do, but certainly there are many ways to skin
a cat.
Dr Sugarbaker. I would respond to your questions, Mark, with
the following. This study in particular has relatively small num-
bers, and I do not think we can make conclusions as to standard
of care from such a study. I think excellent groundwork has been
laid in single institutional trials for a multi-institutional feasibility
trial to see whether this is exportable. However, with all of the dis-
cussion going on about the performance of macroscopic complete
resection by extrapleural pneumonectomy or pleurectomy by those
who think that those 2 operations are done for the same indication,
which they are not, it certainly indicates that, just like with lung
transplantation that we just heard, esophageal cancer, and lobecto-
mies earlier in this meeting, not everybody who does extrapleural
pneumonectomy, particularly at low frequencies, is going to have
the same perioperative mortality. The recent MARS (Mesotheli-
oma And Radical Surgery) trial had an almost 20% operative mor-
tality, an extremely small number of patients, and it really defies
any conclusions at all about the appropriate procedure. As I men-
tioned this morning, depending on disease distribution, eitherry c January 2013
Yellin et al General Thoracic Surgerypleurectomy/decortication or extrapleural pneumonectomy, as
long as you are getting 3% or 4% operative mortality for the pneu-
monectomies, should be applied to get a macroscopic complete re-
section. What we need to do is to move on, as you are suggesting
and as the author here is suggesting, to determine what the betterThe Journal of Thoracic and Cextender of surgical margin is in these 2 tumors that recur locally.
What is the best regimen? I think that is where surgeons and oncol-
ogists should be going. We should drop this idea as to which oper-
ation is better, because it is really 2 different operations for 2
different indications and distributions of disease.ardiovascular Surgery c Volume 145, Number 1 89
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